Athersys
Therapeutic products for the treatment of several disease indications.
Launch date
Employees
Market cap
AUD725k
Enterprise valuation
AUD28m (Public information from Jan 2024)
Share price
$0 ATHX
Cleveland United States (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 5.5m | 1.4m | 5.5m | 5.3m | - | - | - |
| % growth | (77 %) | (74 %) | 285 % | (3 %) | - | - | - |
| EBITDA | (44.8m) | (77.4m) | (85.6m) | (75.6m) | - | - | - |
| % EBITDA margin | (812 %) | (5408 %) | (1553 %) | (1420 %) | - | - | - |
| Profit | (44.6m) | (78.8m) | (87.0m) | (72.5m) | (27.0m) | (25.7m) | (27.2m) |
| % profit margin | (808 %) | (5500 %) | (1577 %) | (1362 %) | - | - | - |
| EV / revenue | 28.7x | 206.1x | 33.5x | 2.6x | - | - | - |
| EV / EBITDA | -3.5x | -3.8x | -2.2x | -0.2x | - | - | - |
| R&D budget | 39.0m | 63.0m | 71.1m | 65.0m | - | - | - |
| R&D % of revenue | 708 % | 4399 % | 1289 % | 1221 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
$13.1m | Post IPO Equity | ||
$20.0m | Post IPO Equity | ||
$9.0m | Post IPO Equity | ||
| N/A | $23.0m | Post IPO Equity | |
* | N/A | $57.6m | Post IPO Equity |
* | N/A | $12.0m | Post IPO Equity |
* | N/A | $3.7m | Post IPO Equity |
* | N/A | $3.5m | Post IPO Equity |
* | N/A | N/A | Post IPO Equity |
* | N/A | N/A | Bankruptcy |
* | N/A | Acquisition | |
| Total Funding | - | ||
Related Content
Recent News about Athersys
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.